CN102655864A - 用于治疗中枢介导的恶心及呕吐的组合物及方法 - Google Patents

用于治疗中枢介导的恶心及呕吐的组合物及方法 Download PDF

Info

Publication number
CN102655864A
CN102655864A CN2010800521070A CN201080052107A CN102655864A CN 102655864 A CN102655864 A CN 102655864A CN 2010800521070 A CN2010800521070 A CN 2010800521070A CN 201080052107 A CN201080052107 A CN 201080052107A CN 102655864 A CN102655864 A CN 102655864A
Authority
CN
China
Prior art keywords
vomiting
day
palonosetron
appropriate smooth
smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800521070A
Other languages
English (en)
Chinese (zh)
Inventor
F·特兰托
S·坎托雷吉
G·罗西
R·坎内拉
D·邦那迪奥
R·布拉利亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102655864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Priority to CN201510047631.3A priority Critical patent/CN104856999A/zh
Priority to CN201510046972.9A priority patent/CN104856998A/zh
Priority to CN201610795817.1A priority patent/CN107050455B/zh
Priority to CN201610797549.7A priority patent/CN106512010A/zh
Priority to CN201610795827.5A priority patent/CN106421793B/zh
Publication of CN102655864A publication Critical patent/CN102655864A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010800521070A 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法 Pending CN102655864A (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201510047631.3A CN104856999A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510046972.9A CN104856998A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795817.1A CN107050455B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610797549.7A CN106512010A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795827.5A CN106421793B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US61/262,470 2009-11-18
US38270910P 2010-09-14 2010-09-14
US61/382,709 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Related Child Applications (5)

Application Number Title Priority Date Filing Date
CN201610797549.7A Division CN106512010A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795827.5A Division CN106421793B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510047631.3A Division CN104856999A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795817.1A Division CN107050455B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510046972.9A Division CN104856998A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法

Publications (1)

Publication Number Publication Date
CN102655864A true CN102655864A (zh) 2012-09-05

Family

ID=43608757

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201610795827.5A Active CN106421793B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795817.1A Active CN107050455B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510047631.3A Pending CN104856999A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610797549.7A Pending CN106512010A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN2010800521070A Pending CN102655864A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510046972.9A Pending CN104856998A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN201610795827.5A Active CN106421793B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610795817.1A Active CN107050455B (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201510047631.3A Pending CN104856999A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN201610797549.7A Pending CN106512010A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510046972.9A Pending CN104856998A (zh) 2009-11-18 2010-11-18 用于治疗中枢介导的恶心及呕吐的组合物及方法

Country Status (40)

Country Link
US (1) US12042494B2 (https=)
EP (3) EP2727590B1 (https=)
JP (1) JP5890780B2 (https=)
KR (1) KR101615108B1 (https=)
CN (6) CN106421793B (https=)
AP (1) AP3083A (https=)
AU (1) AU2010320598B2 (https=)
BR (1) BR112012011485B1 (https=)
CA (1) CA2778301C (https=)
CL (1) CL2012001276A1 (https=)
CO (1) CO6551693A2 (https=)
CR (1) CR20120216A (https=)
CU (1) CU24048B1 (https=)
CY (1) CY1118062T1 (https=)
DK (2) DK2361090T3 (https=)
DO (1) DOP2012000138A (https=)
EA (1) EA026815B1 (https=)
EC (1) ECSP12011907A (https=)
ES (4) ES2623503T3 (https=)
GE (1) GEP20156226B (https=)
GT (1) GT201200156A (https=)
HK (2) HK1214148A1 (https=)
HR (3) HRP20140759T1 (https=)
HU (1) HUE029677T2 (https=)
IL (1) IL219576A (https=)
LT (1) LT2722045T (https=)
MA (1) MA33810B1 (https=)
MX (1) MX2012005347A (https=)
MY (1) MY159393A (https=)
NI (1) NI201200090A (https=)
NZ (1) NZ599439A (https=)
PE (1) PE20121483A1 (https=)
PH (1) PH12012500887A1 (https=)
PL (3) PL2361090T3 (https=)
PT (2) PT2361090E (https=)
RS (2) RS55206B1 (https=)
SI (2) SI2361090T1 (https=)
SM (1) SMT201400112B (https=)
TN (1) TN2012000170A1 (https=)
WO (1) WO2011061622A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106902086A (zh) * 2015-12-23 2017-06-30 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
CN111343981A (zh) * 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2013004766A1 (en) * 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CN105412110B (zh) * 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
EP3746078A4 (en) * 2018-02-02 2021-11-17 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) ORAL FORMULATIONS AND USES THEREOF
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049552A1 (en) * 2006-10-24 2008-05-02 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
MXPA03000366A (es) 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
JP4116436B2 (ja) 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）
DE10393729T5 (de) 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049552A1 (en) * 2006-10-24 2008-05-02 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIEMUNCSH P ET AL: "Neurokinin-1 receptor antagonists in the prevention of posioperative nausea and vomiting", 《BRITISH JOURNAL OF ANAESTHESIA 》, vol. 103, no. 1, 31 July 2009 (2009-07-31), pages 7 - 13, XP002626040, DOI: 10.1093/BJA/AEP125 *
REDDY G KESAVA ET AL: "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis", 《SUPPORTIVE CANCER THERAPY》, vol. 3, no. 3, 30 April 2006 (2006-04-30), pages 140 - 142, XP008134130, DOI: 10.3816/SCT.2006.n.011 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106902086A (zh) * 2015-12-23 2017-06-30 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
CN111343981A (zh) * 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Also Published As

Publication number Publication date
AU2010320598B2 (en) 2016-06-16
PT2361090E (pt) 2014-09-03
ES2623503T3 (es) 2017-07-11
CN106512010A (zh) 2017-03-22
EP2727590B1 (en) 2015-10-21
CN106421793A (zh) 2017-02-22
HUE029677T2 (hu) 2017-03-28
AP2012006278A0 (en) 2012-06-30
HK1214148A1 (zh) 2016-07-22
SI2722045T1 (sl) 2017-02-28
MY159393A (en) 2016-12-30
ECSP12011907A (es) 2012-10-30
EA026815B1 (ru) 2017-05-31
DOP2012000138A (es) 2012-11-15
PT2722045T (pt) 2016-10-18
EP2361090A1 (en) 2011-08-31
MA33810B1 (fr) 2012-12-03
AU2010320598A1 (en) 2012-06-14
CN106421793B (zh) 2023-06-16
ES2595077T3 (es) 2016-12-27
US12042494B2 (en) 2024-07-23
RS55206B1 (sr) 2017-01-31
GEP20156226B (en) 2015-01-26
IL219576A0 (en) 2012-06-28
CU24048B1 (es) 2014-12-26
IL219576A (en) 2017-08-31
WO2011061622A1 (en) 2011-05-26
ES2494015T3 (es) 2014-09-12
PL2722044T3 (pl) 2017-08-31
DK2361090T3 (da) 2014-08-25
DK2722045T3 (en) 2016-10-24
LT2722045T (lt) 2016-09-26
PL2722045T3 (pl) 2017-03-31
PL2361090T3 (pl) 2014-10-31
PE20121483A1 (es) 2012-12-02
HRP20140759T1 (hr) 2014-10-24
CA2778301A1 (en) 2011-05-26
CA2778301C (en) 2016-06-14
CO6551693A2 (es) 2012-10-31
CL2012001276A1 (es) 2012-12-07
HRP20161277T1 (hr) 2016-11-18
BR112012011485B1 (pt) 2021-06-29
EP2722044A1 (en) 2014-04-23
MX2012005347A (es) 2012-08-03
RS53491B1 (sr) 2015-02-27
CN107050455A (zh) 2017-08-18
JP5890780B2 (ja) 2016-03-22
EP2727590A1 (en) 2014-05-07
KR20120101456A (ko) 2012-09-13
JP2013511507A (ja) 2013-04-04
GT201200156A (es) 2014-03-27
CR20120216A (es) 2012-07-24
KR101615108B1 (ko) 2016-05-12
CU20120078A7 (es) 2012-10-15
BR112012011485A2 (pt) 2018-04-03
CN107050455B (zh) 2020-09-29
SI2361090T1 (sl) 2014-09-30
AP3083A (en) 2015-01-31
PH12012500887A1 (en) 2016-08-26
CN104856998A (zh) 2015-08-26
EP2722044B1 (en) 2017-01-04
EA201290356A1 (ru) 2012-12-28
ES2559475T3 (es) 2016-02-12
NZ599439A (en) 2014-06-27
HK1214147A1 (zh) 2016-07-22
CN104856999A (zh) 2015-08-26
SMT201400112B (it) 2014-11-10
CY1118062T1 (el) 2017-06-28
TN2012000170A1 (en) 2013-12-12
US20230263799A1 (en) 2023-08-24
HRP20170419T1 (hr) 2017-06-02
NI201200090A (es) 2012-11-13
EP2361090B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
CN102655864A (zh) 用于治疗中枢介导的恶心及呕吐的组合物及方法
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
AU2017288456A1 (en) Vortioxetine dosing regimes for fast onset of antidepressant effect
HK1228787B (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171391

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120905